Evidence map›Paper›PMID 39898646›Full record

ArticleMicrobiology spectrum2025

Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study.

Yujie Zhao, Jacqueline T Ferri, James R White, Megan D Schollenberger, Kim Peloza, Cynthia L Sears, Evan J Lipson, Fyza Y Shaikh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yujie ZhaoDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
Jacqueline T FerriDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
James R WhiteResphera Biosciences, Baltimore, Maryland, USA.
Megan D SchollenbergerDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Kim PelozaDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Cynthia L SearsDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-4059-1661
Evan J LipsonDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Fyza Y ShaikhDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-7839-8483

Funding

Metabolite driven mechanisms by which gut microbes impact checkpoint inhibitor success in non-small cell lung cancer patientsK08CA263316 · NCI · JOHNS HOPKINS UNIVERSITY · PI SHAIKH, FYZA Y · 2021 to 2025
$1.1M
Bristol Myers Squibb Foundation (BMSF)Damon Runyon Cancer Research Foundation (DRCRF)HHS | NIH | National Cancer Institute (NCI) K08CA263316JHU | Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University | Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University (Bloomberg~Kimmel Institute for Cancer Immunotherapy)NCI NIH HHS K08 CA263316The Marilyn and Michael Grossman Fund for Basal Cell Carcinoma and Melanoma Research
6 · The paper itself

Abstract

Immune checkpoint inhibitor (ICI) therapy has yielded revolutionary outcomes among some individuals with skin cancer, but a large percentage of individuals do not benefit from these treatments. The gut microbiota is hypothesized to impact ICI therapy outcomes. However, data on ICI therapy, gut microbiota, and non-melanoma skin cancers are limited. To examine the association of gut microbiota structure and function with non-melanoma skin cancer ICI outcomes, we performed 16S rRNA V1-V2 gene amplicon sequencing of 68 fecal samples collected longitudinally from individuals with basal cell carcinoma (

Indexed as

BacteriaGastrointestinal MicrobiomeImmune Checkpoint InhibitorsSkin NeoplasmsAgedAged, 80 and overBasal Cell CarcinomaCarcinoma, Merkel CellCarcinoma, Squamous CellFecesFemaleHumansMaleMetabolomicsMiddle AgedRNA, Ribosomal, 16SImmune Checkpoint InhibitorsRNA, Ribosomal, 16Sbasal cell carcinomacutaneous squamous cell carcinomaimmune checkpoint inhibitorsMerkel cell carcinomamicrobiome

Identifiers

PMID39898646
PMCPMC11878019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.